Skip to content

In the BioHarmony Drug Report Database

Ibritumomab tiuxetan

Zevalin (ibritumomab tiuxetan) is an antibody pharmaceutical. Ibritumomab tiuxetan was first approved as Zevalin on 2002-02-19. It is used to treat b-cell lymphoma and follicular lymphoma in the USA. It has been approved in Europe to treat follicular lymphoma. The pharmaceutical is active against B-lymphocyte antigen CD20.
Trade Name Zevalin
Common Name Ibritumomab tiuxetan
Indication b-cell lymphoma, follicular lymphoma
Drug Class Monoclonal antibodies; chelating agents
Ibritumomab tiuxetan
Get full access now